Literature DB >> 3876379

Differential interleukin 1 elaboration by unfractionated and density fractionated human alveolar macrophages and blood monocytes: relationship to cell maturity.

J A Elias, A D Schreiber, K Gustilo, P Chien, M D Rossman, P J Lammie, R P Daniele.   

Abstract

The elaboration of interleukin 1 (IL 1) by mononuclear phagocytes is important in the regulation of human inflammatory and fibrotic reactions. Mononuclear phagocytes are morphologically and functionally heterogeneous cells. To further understand the processes controlling inflammation and fibrosis, in particular that in the human lung, we studied the elaboration of IL 1 by unfractionated and density-fractionated human alveolar macrophages and blood monocytes. Stimulated blood monocytes elaborated more IL 1 than stimulated alveolar macrophages. In addition, denser alveolar macrophages and blood monocytes elaborated more IL 1 than less dense alveolar macrophages and monocytes. Lastly, as monocytes matured in vitro, they lost their ability to elaborate IL 1 and became less dense. Thus, there is variability between and within mononuclear phagocyte cell populations in their ability to elaborate IL 1. These differences may result in part from differences in cell maturation.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3876379

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  27 in total

1.  Monocyte heterogeneity in angiotensin-converting enzyme induction mediated by autologous T lymphocytes.

Authors:  J H Ryu; Z Vuk-Pavlović; M S Rohrbach
Journal:  Clin Exp Immunol       Date:  1992-05       Impact factor: 4.330

2.  Differential effects of LPS, IFN-gamma and TNF alpha on the secretion of lysozyme by individual human mononuclear phagocytes: relationship to cell maturity.

Authors:  C E Lewis; S P McCarthy; J Lorenzen; J O McGee
Journal:  Immunology       Date:  1990-03       Impact factor: 7.397

3.  Comparison of human monocytes isolated by elutriation and adherence suggests that heterogeneity may reflect a continuum of maturation/activation states.

Authors:  I Dransfield; D Corcoran; L J Partridge; N Hogg; D R Burton
Journal:  Immunology       Date:  1988-03       Impact factor: 7.397

4.  Increased cyclic AMP levels enhance IL-1 alpha and IL-1 beta mRNA expression and protein production in human myelomonocytic cell lines and monocytes.

Authors:  S S Sung; J A Walters
Journal:  J Clin Invest       Date:  1991-12       Impact factor: 14.808

5.  Regulation of interleukin-1 synthesis by histamine produced by mouse peritoneal macrophages per se.

Authors:  H Okamoto; K Nakano
Journal:  Immunology       Date:  1990-01       Impact factor: 7.397

6.  Fibroblast interleukin 1 beta: synergistic stimulation by recombinant interleukin 1 and tumor necrosis factor and posttranscriptional regulation.

Authors:  J A Elias; M M Reynolds; R M Kotloff; J A Kern
Journal:  Proc Natl Acad Sci U S A       Date:  1989-08       Impact factor: 11.205

7.  Productive infection of isolated human alveolar macrophages by respiratory syncytial virus.

Authors:  J R Panuska; N M Cirino; F Midulla; J E Despot; E R McFadden; Y T Huang
Journal:  J Clin Invest       Date:  1990-07       Impact factor: 14.808

8.  The production of TNF-alpha and IL-1-like activity by bronchoalveolar leucocytes after intratracheal instillation of crocidolite asbestos.

Authors:  X Y Li; D Lamb; K Donaldson
Journal:  Int J Exp Pathol       Date:  1993-08       Impact factor: 1.925

9.  In vitro interleukin-1 (IL-1) production in thymic hyperplasia and thymoma from patients with myasthenia gravis.

Authors:  C Aime; S Cohen-Kaminsky; S Berrih-Aknin
Journal:  J Clin Immunol       Date:  1991-09       Impact factor: 8.317

10.  Human alveolar macrophages infected by virulent bacteria expressing SipB are a major source of active interleukin-18.

Authors:  Carolina Obregon; Donatus Dreher; Menno Kok; Laurence Cochand; Gitahi S Kiama; Laurent P Nicod
Journal:  Infect Immun       Date:  2003-08       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.